Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.14) b...
Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated...
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...
William Blair analyst Matt Phipps initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating.
BTIG analyst Julian Harrison reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $8 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and annou...
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $7 to $8.
